Table 3.

In vitro anti-proliferative activity (IC₅₀, μM)^a of the compounds against prostate cancer cell lines

Comp. No	IC50 (μM)			IC50 (silibinin)/IC50 (derivitive)
	LNCaP b	DU145 c	PC-3d	LNCaP	DU145	PC-3
Silibinin (1)	43.03 ± 7.84	93.34 ± 13.76	72.65 ± 3.15	1	1	1
2	3.09 ± 1.30	11.48 ± 1.42	9.45 ± 0.56	14	8	8
3	8.14 ± 2.35	21.64 ± 0.53	12.58 ± 1.28	5	4	6
4	3.22 ± 0.59	16.44 ± 0.49	7.52 ± 0.22	14	6	10
5	2.07 ± 0.18	11.04 ± 0.68	1.71 ± 0.45	21	8	42
6	1.99 ± 0.10	14.36 ± 0.40	2.29 ± 0.12	22	7	32
7	2.07 ± 0.35	14.03 ± 0.66	3.06 ± 0.48	21	7	24
8	3.50 ± 0.21	21.11 ± 0.76	6.04 ± 0.80	12	4	12
9	3.96 ± 0.38	19.24 ± 0.88	10.66 ± 1.62	11	5	7
10	3.77 ± 0.40	17.76 ± 1.98	4.46 ± 2.24	11	6	16

^aIC₅₀ is the drug concentration effective in inhibiting 50% of the cell viability measured by the WST-1 cell proliferation Assay after 3 days exposure.

^bHuman androgen-sensitive prostate cancer cell line

^cHuman androgen-independent prostate cancer cell line

^dHuman androgen-independent prostate cancer cell line